ROSSELL-TECHSYS
26.8.2020 12:32:14 CEST | Business Wire | Press release
Rossell Techsys (Division of Rossell India Limited) has been named a global Supplier of the Year by aerospace major Boeing. The award in the Production category is for being instrumental in the design, modification or production of a product, for 2019.
“Rossell Techsys contributes high quality components for some of Boeing’s most advanced platforms and we are proud to partner with them. Achieving the Supplier of the Year distinction for the second time is an acknowledgement of Rossell Techsys’ capabilities,” said Salil Gupte, president, Boeing India . “Boeing continues to grow a globally competitive supplier base in India, with strong partnerships that are aligned with the government’s Aatmanirbhar Bharat vision,” he added.
“We are delighted and grateful to receive the Supplier of the Year award from Boeing, for the second time in five years. Our long-term strategy of targeted investments in aerospace and defense continues to reap rich dividends, enhancing customer confidence and trust. We are thankful to Boeing for this recognition,” said Rishab Mohan Gupta, Director, Rossell India Limited.
“We are humbled to be chosen by Boeing for this award, among 12,000 active global suppliers. This award is a testimony to Rossell Techsys’ manufacturing capabilities and customer focus. We believe this is also a recognition of the rising stature of India in global Aerospace and Defense manufacturing,” said Prabhat Kumar Bhagvandas, Chief Executive Officer, Rossell Techsys.
Rossell Techsys is based in Bangalore, India, and supplies engineering, manufacturing, test, and product support solutions to global aerospace and defense OEMs. For Boeing, Rossell Techsys provides manufacturing services for Interconnect Systems, such as wire harnesses and electrical/cockpit panels. Key Boeing platforms supported by Rossell Techsys include the F/A-18, F-15, AH-64, CH-47, V-22, KC-46, P-8, and T-7A.
About Rossell Techsys
Rossell Techsys is the Aerospace & Defense Division of Rossell India Limited, a public listed company. It is at the forefront of the “Made in India’ brand of excellence committed to “finish and finesse”. It is AS9100, ISO 9001, ISO 14001, ISO 45001, ISO 27001, ISO 37001 certified, and ISO 31000 compliant. It has instituted paperless, green manufacturing processes in its LEED rated 250,000-square-foot facility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom